搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
PharmaTimes
3 天
Bayer begins inhibitor study treating advanced KRAS-mutated tumours
Trial explores potential of therapy in treating multiple cancer types Bayer has begun a phase 1 clinical trial for BAY3498264 ...
PharmaTimes
5 天
CatalYm shows potential of visugromab for treating cachexia
CatalYm has announced promising new data on its lead drug candidate, visugromab, at the 17th International Conference on ...
PharmaTimes
5 天
Cellenkos presents promising phase 1b data for CK0804 in myelofibrosis
New cell therapy shows potential in treating advanced blood disorder Cellenkos has unveiled new phase 1b data for its ...
PharmaTimes
12 天
KIMMTRAK recommended for funding by NICE for uveal melanoma patients
Immunocore has announced that Kimmtrak (tebentafusp) has been recommended for funding in England by the National Institute ...
PharmaTimes
13 天
Pharma giants vie for oral GLP-1R approval
Jasper Morley, Pharma Analyst at GlobalData, explains the significance: “Novo Nordisk and Eli Lilly are leading the charge to ...
PharmaTimes
6 天
Imfinzi receives NICE recommendation for lung cancer treatment
AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended by NICE for treating adults with ...
PharmaTimes
6 天
Poolbeg Pharma presents positive results for POLB 001
The positive pre-clinical results underpin the development of POLB 001 for Phase 2 clinical trials as a prophylactic for ...
PharmaTimes
11 天
Everest therapy shows promise in nephropathy trial
Everest Medicines has announced promising results from the Phase 1b/2a clinical trial of EVER001, a novel Bruton’s tyrosine ...
PharmaTimes
4 天
Leriglitazone meets endpoint in trial for cerebral adrenoleukodystrophy
Minoryx Therapeutics and Neuraxpharm Group have announced that leriglitazone met the primary endpoint in the NEXUS trial for ...
PharmaTimes
10 天
Teva’s Ajovy shows positive results in preventing pediatric migraines
Teva Pharmaceutical Industries has presented positive data from its Phase 3 SPACE study, demonstrating the efficacy and ...
PharmaTimes
10 天
NICE endorses Neuraxpharm’s ublituximab for treating MS
Neuraxpharm Group has announced that the National Institute for Health and Care Excellence (NICE) has recommended ublituximab ...
PharmaTimes
17 天
New injection offers hope for asthma and COPD attacks
A new treatment for asthma and COPD attacks could revolutionise patient care, scientists say. An injection given during ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈